Gilead Report Highlights RNA Therapeutic Progress: GSK/Ionis HBV ASO Shows Positive Phase 3, Novartis FSHD siRNA Promising Early Data

August 17, 2026

The Bio Report USA

Overview

A Gilead report underscores significant advancements in RNA therapeutic clinical trials, with GSK/Ionis’s beoprovirsen, an ASO targeting HBV, demonstrating positive Phase 3 results. Novartis’s siRNA therapy, Delbra, for facioscapulohumeral muscular dystrophy (FSHD), also shows promising early-stage data. However, the Phase 3 results for Novartis/Ionis’s Lp(a)-targeting ASO, Pelaren, have been delayed. These developments highlight the high expectations placed on RNA therapeutics across various disease areas, but also the challenges in their late-stage development.

In Depth

Key Findings

Gilead’s latest report has highlighted notable advancements in RNA therapeutic clinical trials. Beoprovirsen, an antisense oligonucleotide (ASO) targeting hepatitis B virus (HBV), co-developed by GSK and Ionis, is reported to have achieved positive results in its Phase 3 trials. Additionally, Novartis’s siRNA therapy, Delbra, for facioscapulohumeral muscular dystrophy (FSHD), has shown promising early-stage data. Conversely, a delay has occurred in the Phase 3 trial results for Pelaren, an Lp(a)-targeting ASO developed through a partnership between Novartis and Ionis. This information illuminates both the progress and challenges within RNA therapeutics development.

Technical / Clinical Details

Beoprovirsen is an ASO designed to suppress HBV gene expression, thereby inhibiting viral replication and aiming for a functional cure for hepatitis B. The positive Phase 3 results suggest long-term viral control and clinical efficacy for patients with chronic HBV infection, potentially offering a new option for existing treatments. Delbra aims to halt disease progression in FSHD by silencing the abnormal expression of the DUX4 gene, which is the causative gene for FSHD, using siRNA technology. Early-stage data indicate the potential of RNAi technology for rare genetic disorders like FSHD, with further clinical development anticipated. Pelaren is an ASO designed to lower levels of lipoprotein(a) [Lp(a)], a cardiovascular disease risk factor; the delay in Phase 3 results suggests unforeseen complexities in clinical development.

Background & Context

RNA therapeutics have become a major focus in the pharmaceutical industry since their rapid development capability and efficacy were widely recognized with the success of mRNA vaccines during the COVID-19 pandemic. ASOs and siRNAs, capable of targeting specific gene expression to address the root causes of diseases, hold the potential to deliver groundbreaking therapies across a wide range of disease areas, including genetic disorders, infectious diseases, and cardiovascular conditions. The fact that a major pharmaceutical company like Gilead references the progress of these RNA therapeutics in its strategic report underscores the strategic importance of this modality for the entire industry.

Strategic Significance & Outlook

The positive Phase 3 results for beoprovirsen represent a significant advance in the treatment of chronic hepatitis B, offering new hope to many patients if approved and launched. Delbra’s early success in FSHD expands the potential application of RNAi technology for rare genetic muscle diseases. The delay for Pelaren is unfortunate, but lowering Lp(a) remains crucial for reducing cardiovascular disease risk, and results are highly anticipated. Overall, RNA therapeutics, with their precise targeting capabilities and diverse mechanisms of action, are expected to continue active research and development as a leading class of next-generation therapies addressing unmet medical needs. These clinical outcomes will significantly influence the market introduction and widespread adoption of RNA-based medicines globally.

Source: https://thebioreport.com/articles/how-gilead-is-building-durable-oncology-and-immunology-franchises/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.